Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Phase 1 Terminated 18 enrolled Abramson Cancer Center at Penn Medicine

NaSingle-groupOpen-labelTreatment

Summary

This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer. (Funding Source - FDA OOPD)

Timeline

Start: 2011-03
Primary completion: 2015-10
Completion: 2019-01

Publications

Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, Petremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Sternberg M, Powell DJ Jr, June CH, Dafni U, Kandalaft LE, Harari A, Coukos G. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nat Cancer. 2023 Oct;4(10):1410-1417. doi: 10.1038/s43018-023-00623-x. Epub 2023 Sep 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	OC-DC vaccine	Vaccine	5e+06 cells	Other
Subject	OC-DC vaccine	Vaccine	1e+07 cells	Other
Subject	therapeutic autologous lymphocytes	Cell therapy	1e+10 cells	Intravenous
Subject	therapeutic autologous lymphocytes	Cell therapy	1.5e+10 cells	Intravenous
Background	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous
Background	Fludarabine	Small molecule	30 mg/m2	Intravenous

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications